Press Releases

 
Press Releases
  Date Title View
Jan 12, 2018
CTP-543 is a Novel JAK Inhibitor in Phase 2 for Alopecia Areata as Potential First-in-Class Treatment LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation ...
Jan 12, 2018
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has decided not to grant the Company's Post Grant Review (PGR) petition challenging the validity of U.S. Patent No. 9,662,...
Dec 18, 2017
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the appointment of Marc Becker as Chief Financial Officer, effective January 4, 2018. Mr. Becker is a seasoned financial executive with more than 15 years of experience in the biotechnology industry. ...
Dec 13, 2017
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 18, 2017. The NASDAQ Biotechnology Index is design...
Nov 9, 2017
Conference Call Scheduled Today at 8:30 a.m. EST LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2017. "This is an exciting time for our deuterium-based chemistry as we ...
Nov 6, 2017
CTP-543 is Being Evaluated in Moderate-to-Severe Alopecia Areata Phase 2a Trial On Track to Complete in Second Half of 2018 LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed enrollment of the first ...
Nov 2, 2017
Oct 19, 2017
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trials and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has denied Incyte's petition to institute inter partes review (IPR) of U.S. Patent No. 9,249,149 (the ‘149 patent)....
Aug 31, 2017
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Wells Fargo 2017 Healthcare Conference on Thursday, September 7, 2017, at 11:10 a.m. EDT at the Westin Waterfront in Boston. A live we...
Aug 8, 2017
Conference Call Scheduled Today at 8:30 a.m. EDT LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2017. "We are very pleased that we have closed the CTP-656 asset purchase ...
1
...
NextLast
= add release to Briefcase